RVL Pharmaceuticals

RVL Pharmaceuticals Interest Coverage

The Interest Coverage Ratio of RVL Pharmaceuticals (RVLPQ) as of Nov 16, 2026 is -152.27. In the previous year, Interest Coverage Ratio was -20.13 — a change of 656.51% (lower).

Interest Coverage

-152.27

YoY

656.51%

Last updated:

Interest Coverage Ratio of RVL Pharmaceuticals is 2022 -152.27 . Interest Coverage Ratio of RVL Pharmaceuticals was 2021 -20.13 . It decreases by 656.51% lower compared to the previous year.

The RVL Pharmaceuticals Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2016
-1.59 USD
Jan 1, 2017
-1.79 USD
Jan 1, 2018
-4.74 USD
Jan 1, 2019
0.22 USD
Jan 1, 2020
-4.29 USD
Jan 1, 2021
-20.13 USD
Jan 1, 2022
-152.27 USD
The RVL Pharmaceuticals Interest Coverage history
YEARInterest CoverageYoY
-152.27+656.51%
-20.13+369.43%
-4.29-2,082.60%
0.22-104.57%
-4.74+164.76%
-1.79+12.78%
-1.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RVL Pharmaceuticals Stock analysis

What does RVL Pharmaceuticals do? Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RVL Pharmaceuticals stock

Interest Coverage Ratio of RVL Pharmaceuticals is -152.27 in 2022.

Interest Coverage Ratio of RVL Pharmaceuticals changed from -20.13 to -152.27, representing a 656.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio RVL Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's RVL Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RVL Pharmaceuticals

All Key Metrics — RVL Pharmaceuticals